이뮨온시아
Financials
Valuation Metrics
이뮨온시아's Market Cap is ₩2761B. Ranked #670 of 2,436 in KR market (top 28%), #271 of 1,649 on KOSDAQ (top 16%), #76 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 276.10B KRW | KR#670/2,436 Sec#76/234 |
| Revenue | 111.2M KRW | KR#2,401/2,436 Sec#227/234 |
| Net Income | -27.36B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 33.15B KRW | KR#2,307/2,436 Sec#218/234 |
| Net Assets | 28.42B KRW | KR#2,180/2,436 Sec#196/234 |
| Value | ||
| P/B | 9.72x | KR#2,342/2,436 Sec#209/234 |
| P/S | 2482.71x | KR#2,418/2,436 Sec#227/234 |
| FCF Yield | -8.37% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -96.30% | KR#2,341/2,436 Sec#219/234 |
| ROA | -82.55% | KR#2,379/2,436 Sec#228/234 |
| Op. Margin | -25182.04% | KR#2,401/2,436 Sec#227/234 |
| Financial Health | ||
| Debt Ratio | 116.65% | KR#581/2,436 Sec#75/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -23.10B KRW | KR#1,937/2,436 Sec#187/234 |
| Cash | 8.24B KRW | KR#1,782/2,436 Sec#151/234 |
| Current Ratio | 6.22x | KR#215/2,436 Sec#47/234 |
| Performance | ||
| 1Y Return | -41.00% | KR#1,860/2,436 Sec#165/234 |
| 1M Return | -11.16% | KR#1,833/2,436 Sec#185/234 |
| From 52W High | -80.48% | KR#2,360/2,436 Sec#224/234 |
| 1Y MDD | -83.48% | KR#2,351/2,436 Sec#225/234 |
| Trading | ||
| Volume | 447,995 shares | KR#306/2,436 Sec#35/234 |
| Foreign Own. | 4.11% | KR#879/2,436 Sec#85/234 |
| Per Share | ||
| EPS | -346 KRW | KR—/2,436 Sec—/234 |
| BPS | 289 KRW | KR#2,420/2,436 Sec#232/234 |
Company Info
IMMUNEONCIA, established in 2016, is a specialized company developing antibody-based immune-oncology drugs, slated for KOSDAQ listing in 2025 as a technology growth company. It holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as core assets, generating revenue through new drug candidate development and early clinical technology transfers. IMMUNEONCIA aims to be the first domestic leader in commercializing Anti-PD-L1 immune-oncology drugs and is concentrating on research and development to launch global blockbuster new drugs. Its headquarters are located in Yongin-si, Gyeonggi-do.